Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes.We recently synthesized the 3,5-C12-EG-(OH)4 dendrimer that generates dendrimersomes with very promising safety and stability profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C18)2 and the glucocorticoid drug Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tumour models. The incorporation of GdDOTAGA(C18)2 into the membrane resulted in dendrimersomes with a high longitudinal relaxivity (r1 = 39.1 mM−1 s−1, at 310 K and 40 MHz) so that, after intravenous administration, T1-weighted MRI showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical theranostic applications.

First in vivo MRI study on theranostic dendrimersomes

CATANZARO, Valeria;BOTTA, Mauro;TEI, LORENZO;
2017-01-01

Abstract

Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes.We recently synthesized the 3,5-C12-EG-(OH)4 dendrimer that generates dendrimersomes with very promising safety and stability profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C18)2 and the glucocorticoid drug Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tumour models. The incorporation of GdDOTAGA(C18)2 into the membrane resulted in dendrimersomes with a high longitudinal relaxivity (r1 = 39.1 mM−1 s−1, at 310 K and 40 MHz) so that, after intravenous administration, T1-weighted MRI showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical theranostic applications.
File in questo prodotto:
File Dimensione Formato  
Accepted version.pdf

file ad accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF Visualizza/Apri
JControlledRelease 2017, 248, 45–52.pdf

file disponibile solo agli amministratori

Tipologia: Versione Editoriale (PDF)
Licenza: DRM non definito
Dimensione 690.02 kB
Formato Adobe PDF
690.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11579/82134
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 35
social impact